EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

“Mycophenolate‐Based Immunosuppression After Calcineurin‐Inhibitor Withdrawal in Liver Transplant Recipients is Safe and Results in Long‐Term Improvement in Renal Function”

Nicholas Lim iD, David Vock iD, Scott Jackson iD, John Lake iD

Clinical Transplantation · 2026-06 · 40 (6)

DOI: 10.1111/ctr.70590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 15.06.2026. Verfasst von Nicholas Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Calcineurin Inhibitors, Immunosuppressive Agents, Graft Rejection. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Renal dysfunction is an important side effect of calcineurin inhibitors (CNI) and is associated with worse outcomes after liver transplantation (LT). Prior studies on mycophenolate‐based (MMF), CNI‐free immunosuppression regimens have raised concerns about the risk of rejection (ACR). We evaluated the long‐term impact of transition from CNI to MMF‐based immunosuppression on long‐term renal function and other clinical outcomes.

Methods

We performed a single‐center, retrospective review of LT recipients from 1/1/2008 to 12/31/2021 who were transitioned from CNI‐ to MMF‐based immunosuppression for renal dysfunction. Primary outcome was mean change in eGFR at 1‐ and 5‐years after CNI withdrawal: a sequential stratification model was then used to compare changes in eGFR to a control group comprising patients maintained on CNIs at last follow‐up date. Secondary outcomes included first episode of acute cellular rejection (ACR), graft survival and patient survival.

Results

Fifty‐one patients were switched to a MMF‐based immunosuppression regimen at median time of 29.1 months after LT and were then followed for median 93.2 months. Mean age at time of LT was 57.5 years old, 41 (80.4%) patients were male, 44 (86.3%) patients were white and 16 (32.7%) patients had a history of hepatitis C. Model‐based estimates of the increase in eGFR‐CKD‐Epi were 5.7 (95% CI: 2.4, 9.0, p = 0.001) mL/min per 1.73 m 2 and 10.2 (95% CI: 5.0, 15.3, p < 0.001) mL/min per 1.73 m 2 between baseline and 1‐year and between baseline and 5‐years after CNI withdrawal. On multivariable analysis, CNI withdrawal was not associated with an increased risk of ACR (HR 2.22, 95% CI (0.79, 6.23), p = 0.13).

Conclusions

The use of MMF‐based immunosuppression after CNI withdrawal results in long‐term improvement in renal function without significantly increasing the risk of ACR. As more LT recipients present with and develop renal dysfunction in the post‐MELD era, conversion to a MMF‐based immunosuppression to preserve kidney function is both safe and effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationCalcineurin InhibitorsImmunosuppressive AgentsGraft RejectionMycophenolic AcidPostoperative ComplicationsHumansFemaleMaleRetrospective StudiesFollow-Up StudiesGraft SurvivalPrognosisMiddle AgedGlomerular Filtration RateKidney Function TestsRisk FactorsTreatment InterruptionSurvival Rate

Stichwörter der Autor:innen

calcineurin‐inhibitorimmunosuppressionkidney functionliver transplant

Substanzen

Calcineurin InhibitorsImmunosuppressive AgentsMycophenolic Acid

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Gastroenterology and Hepatology, University of Rochester, Rochester, New York, USA.
  • Transplant Institute, University of Rochester, Rochester, New York, USA.
  • Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Analytics Consulting Services, M Health Fairview, Minneapolis, Minnesota, USA.
  • Department of Radiation Oncology, Stanford University, Palo Alto, California, USA.

ORCID-Profile: Nicholas Lim, David Vock, Scott Jackson, John Lake

Zitieren

APA

Lim, N., Vock, D., Jackson, S., & Lake, J. (2026). “Mycophenolate‐Based Immunosuppression After Calcineurin‐Inhibitor Withdrawal in Liver Transplant Recipients is Safe and Results in Long‐Term Improvement in Renal Function”. Clinical Transplantation, 40(6). https://doi.org/10.1111/ctr.70590

Vancouver

Lim N, Vock D, Jackson S, Lake J. “Mycophenolate‐Based Immunosuppression After Calcineurin‐Inhibitor Withdrawal in Liver Transplant Recipients is Safe and Results in Long‐Term Improvement in Renal Function”. Clinical Transplantation. 2026;40(6). doi:10.1111/ctr.70590

BibTeX
@article{Lim2026,
  author = {Lim, Nicholas and Vock, David and Jackson, Scott and Lake, John},
  title = {“Mycophenolate‐Based Immunosuppression After Calcineurin‐Inhibitor Withdrawal in Liver Transplant Recipients is Safe and Results in Long‐Term Improvement in Renal Function”},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {6},
  doi = {10.1111/ctr.70590}
}
Kostenlos starten →